Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LABCORP HOLDINGS INC.LH · Entity 1277 | EVP, Pres Diagnostics & COO | March 26, 2026 | March 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LABCORP HOLDINGS INC.
Report date March 26, 2026 · Filed March 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,677.1426 |
Ending reported balance
After 2026-03-26 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-26 · Grant · Acquired 9,304 · Balance 15,777.1426 F1: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Row 2 · 2026-03-26 · Tax withholding · Disposed 4,600 · Balance 11,177.1426 F2: Stock withholding to satisfy tax withholding obligations. Row 3 · 2026-03-26 · Grant · Acquired 2,968 · Balance 14,145.1426 F3: Shares acquired on March 26, 2026, pursuant to a performance award granted on May 5, 2023, relating to performance during the three-year period ended December 31, 2025. Row 4 · 2026-03-26 · Tax withholding · Disposed 1,468 · Balance 12,677.1426 F2: Stock withholding to satisfy tax withholding obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.
F2: Stock withholding to satisfy tax withholding obligations.
F3: Shares acquired on March 26, 2026, pursuant to a performance award granted on May 5, 2023, relating to performance during the three-year period ended December 31, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2024 Filed Feb 8, 2024 20:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 138 | $223.71 | $30,871.98 |
DisclosureSEC source: 0001127602-24-003954 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500.1426 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003954 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,638.1426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 6,900 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003954 · form4.xml · derivative · entry 6 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 6,900 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 2,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003954 · form4.xml · derivative · entry 5 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,773 Underlying: Common Stock · 2,230 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 20:52 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003545 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,543 Underlying: Common Stock · 495 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested. F4 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 269 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 20:52 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 132 | $221.54 | $29,243.28 |
DisclosureSEC source: 0001127602-24-003545 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,121.1426 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 70.7404 shares acquired on May 31, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 20:52 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003545 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,253.1426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 70.7404 shares acquired on May 31, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 00:06 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 11,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020296 · form4.xml · derivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,769 Underlying: Common Stock · 11,648 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| May 18, 2023 Filed May 22, 2023 19:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionNon-qualified Stock Options · Derivative | 1,500 | $0.00 Strike: $130.60 | $0.00 |
DisclosureSEC source: 0001127602-23-016422 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,900 Underlying: Common Stock · 1,500 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| May 18, 2023 Filed May 22, 2023 19:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 1,500 | $216.77 | $325,155.00 |
DisclosureSEC source: 0001127602-23-016422 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,687.4022 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 18, 2023 Filed May 22, 2023 19:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,500 | $130.60 | $195,900.00 |
DisclosureSEC source: 0001127602-23-016422 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,187.4022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 440 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015024 · form4.xml · derivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,121 Underlying: Common Stock · 440 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 1,400 | $0.00 Strike: $223.86 | $0.00 |
DisclosureSEC source: 0001127602-23-015024 · form4.xml · derivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400 Underlying: Common Stock · 1,400 shares Expires 2033-05-04 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 14:05 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 3,897 | $225.81 | $879,981.57 |
DisclosureSEC source: 0001127602-23-011746 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,687.4022 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:05 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 2,866 | $224.70 | $643,990.20 |
DisclosureSEC source: 0001127602-23-011746 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,584.4022 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:05 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantCommon Stock | 6,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011746 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,450.4022 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 17:51 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 309 | $247.63 | $76,517.67 |
DisclosureSEC source: 0001127602-23-005485 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,687.4022 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:54 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 114 | $248.13 | $28,286.82 |
DisclosureSEC source: 0001127602-23-005100 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,996.4022 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:54 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 423 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005100 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,681 Underlying: Common Stock · 423 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:54 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 423 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005100 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,110.4022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 14:04 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 4,400 | $0.00 Strike: $247.24 | $0.00 |
DisclosureSEC source: 0001127602-23-004096 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2033-02-06 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 14:04 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 1,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004096 · form4.xml · derivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,104 Underlying: Common Stock · 1,390 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 14:04 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 409 | $243.01 | $99,391.09 |
DisclosureSEC source: 0001127602-23-004096 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,687.4022 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 19:50 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 151 | $244.50 | $36,919.50 |
DisclosureSEC source: 0001127602-23-003700 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,096.4022 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2023 Filed Feb 7, 2023 19:50 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003700 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,714 Underlying: Common Stock · 560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 4, 2021 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 4, 2021 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2023 Filed Feb 7, 2023 19:50 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003700 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,247.4022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 03, 2023 Filed Feb 6, 2023 20:51 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 324 | $253.90 | $82,263.60 |
DisclosureSEC source: 0001127602-23-003538 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,687.4022 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 20:51 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 443 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003538 · form4.xml · derivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,274 Underlying: Common Stock · 443 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 20:51 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 119 | $254.99 | $30,343.81 |
DisclosureSEC source: 0001127602-23-003538 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,011.4022 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 20:51 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 443 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003538 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,130.4022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 13:40 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 1,116 | $232.67 | $259,659.72 |
DisclosureSEC source: 0001127602-22-025222 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,687.4022 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 894 | $233.77 | $208,990.38 |
DisclosureSEC source: 0001127602-22-025109 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,803.4022 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 81.9033 shares acquired on June 30, 2022 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| November 05, 2022 Filed Nov 8, 2022 21:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 2,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025109 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,717 Underlying: Common Stock · 2,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on November 5, 2020 and are now fully vested. F4 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on November 5, 2020 and are now fully vested. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 05, 2022 Filed Nov 8, 2022 21:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 2,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-025109 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,697.4022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 81.9033 shares acquired on June 30, 2022 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 14:24 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 2,356 | $277.11 | $652,871.16 |
DisclosureSEC source: 0001127602-22-010699 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,605.4989 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 28, 2022 Filed Mar 29, 2022 16:03 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,885 | $276.42 | $521,051.70 |
DisclosureSEC source: 0001127602-22-010502 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,961.4989 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 27, 2022 Filed Mar 29, 2022 16:03 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantCommon Stock | 4,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-010502 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,846.4989 F1 · kind: Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 20:05 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 207 | $273.98 | $56,713.86 |
DisclosureSEC source: 0001127602-22-005446 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,605.4989 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:38 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 77 | $272.68 | $20,996.36 |
DisclosureSEC source: 0001127602-22-005020 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,812.4989 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:38 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 284 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005020 · form4.xml · derivative · entry 5 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,727 Underlying: Common Stock · 284 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:38 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005020 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,889.4989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:38 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 4,500 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-005020 · form4.xml · derivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2032-02-10 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:38 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 1,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005020 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,011 Underlying: Common Stock · 1,270 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 16:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 204 | $277.38 | $56,585.52 |
DisclosureSEC source: 0001127602-22-003647 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,605.4989 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003647 · form4.xml · derivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,741 Underlying: Common Stock · 560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 152 | $277.48 | $42,176.96 |
DisclosureSEC source: 0001127602-22-003647 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,809.4989 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:08 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003647 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,961.4989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 17:15 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 161 | $271.81 | $43,761.41 |
DisclosureSEC source: 0001127602-22-003291 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,401.4989 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 17:15 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 443 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003291 · form4.xml · derivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,301 Underlying: Common Stock · 443 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 17:15 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 121 | $273.18 | $33,054.78 |
DisclosureSEC source: 0001127602-22-003291 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,562.4989 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.